Emergent BioSolutions (EBS) Non-Current Assets (2010 - 2026)

Emergent BioSolutions' Non-Current Assets history runs 17 years deep, the most recent figure standing at $682.8 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 5.07% year-over-year to $682.8 million; the TTM figure through Mar 2026 stood at $2.7 billion (down 14.91% YoY), while the FY2025 annual figure was $656.1 million, down 17.05% from the prior year.
• Non-Current Assets was $682.8 million for Q1 2026 at Emergent BioSolutions, up from $656.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $2.0 billion in Q4 2022 to a low of $656.1 million in Q4 2025.
• Historically, Non-Current Assets has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets climbed 15.88% in 2022, then tumbled 41.53% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $2.0 billion in 2022, then sank by 41.53% to $1.1 billion in 2023, then sank by 30.84% to $791.0 million in 2024, then declined by 17.05% to $656.1 million in 2025, then grew by 4.07% to $682.8 million in 2026.
• The last three Non-Current Assets figures came in at $682.8 million (Q1 2026), $656.1 million (Q4 2025), and $674.1 million (Q3 2025), per Business Quant data.